## AGN-195183

Cat. No.:	HY-16684					
CAS No.:	367273-07-2	2		O F		
Molecular Formula:	$C_{22}H_{22}ClF_2N$	0 <sub>4</sub>				
Molecular Weight:	437.86					
Target:	RAR/RXR; A	F N H				
Pathway:	HO Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor; Autophagy					
Storage:	Powder	-20°C	3 years			
		4°C	2 years			
	In solvent	-80°C	2 years			
		-20°C	1 year			

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 11 mg/mL (25.12 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	2.2838 mL	11.4192 mL	22.8384 mL		
		5 mM	0.4568 mL	2.2838 mL	4.5677 mL		
		10 mM	0.2284 mL	1.1419 mL	2.2838 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.1 mg/mL (2.51 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.1 mg/mL (2.51 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.1 mg/mL (2.51 mM); Clear solution						

BIOLOGICAL ACTIV	
51020010,12710111	
Description	AGN-195183 (IRX-5183) is a potent and selective agonist of RARα (K <sub>d</sub> =3 nM) with improved binding selectivity relative to AGN 193836. AGN-195183 has no activity on RARβ/γ.
IC <sub>50</sub> & Target	IC50 value: 3 nM (Kd); 200 nM (EC80, RAR Trans)
In Vitro	AGN-195183 (IRX-5183; Compound 4) inhibits the growth of breast cancer cell lines, and is inactive in an in vivo model of topical irritation.AGN-195183 and ATRA inhibit growth of the human breast cancer cell lines, T-47D and SK-BR-3. AGN-



195183 does not cause the topical irritation induced by the RARa-selective retinoid, Am-580. AGN-195183 is currently in Phase I/IIA clinical trials in cancer patients. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Beard RL, et al. Synthesis and biological activity of retinoic acid receptor-alpha specific amides. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3145-8.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA